In the News

OncLive

June 22, 2023

In 2011, the development of ipilimumab, a novel antibody targeting the CTLA-4 immune checkpoint, helped launch the modern era of anticancer immunotherapy.

OncLive

April 7, 2023

For many patients, there is no greater sense of promise than cancer immunotherapy and it is often the first inquiry we receive. Of course, the concept of cancer immunotherapy is not new, dating back 150 years when William B.

Targeted Oncology

March 27, 2023

Results from the phase 1/2 study were presented by Bockorny, the principal investigator, during The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer. Results suggested that the clinical benefit of botensilimab plus bastiliimab was superior to that of standard-of-care therapy.

OncLive

March 27, 2023

Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.